Bevacizumab (avastin, recombinant humanized monoclonal Ab to VEGF) is currently used for treatment of metastatic colorectal cancer, non-sqamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, metastatic or recurrent cervical cancer (in combination with chemotherapy), platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with chemotherapy. Here, VEGFA is linked to metastatic colorectal cancer.